GSA Capital Partners’s Milestone Pharmaceuticals MIST Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$22K Buy
+25,468
New +$28.3K ﹤0.01% 1809
2026
Q2
– Sell
-26,893
Closed -$32K – 2001
2026
Q1
$32K Sell
26,893
-209,245
-89% -$366K ﹤0.01% 1627
2025
Q4
$477K Buy
236,138
+157,391
+200% +$339K 0.04% 842
2025
Q3
$157K Buy
+78,747
New +$138K 0.01% 1475
2023
Q4
– Sell
-48,796
Closed -$151K – 1755
2023
Q3
$151K Sell
48,796
-17,544
-26% -$54.5K 0.01% 1339
2023
Q2
$189K Sell
66,340
-33,428
-34% -$126K 0.02% 1290
2023
Q1
$393K Buy
+99,768
New +$365K 0.04% 862

Other funds holding MIST

GSA Capital Partners's MIST Position: Q3 2026 in Review

GSA Capital Partners opened a new position in Milestone Pharmaceuticals (MIST) in Q3 2026: 25,468 shares worth $22K. The stake represents ﹤0.01% of the portfolio and ranks #1809 among its holdings. This is a return to the name: GSA Capital Partners previously reported a position in MIST as recently as Q1 2026.

GSA Capital Partners first reported a position in MIST in Q1 2023 and has held it in 7 quarters since. The position peaked at $477K in Q4 2025. 74 funds tracked by Wall St. Rank hold MIST as of Q3 2026.

  • GSA Capital Partners held 25,468 shares of Milestone Pharmaceuticals worth $22K as of Q3 2026.
  • Milestone Pharmaceuticals was a new GSA Capital Partners position in Q3 2026.
  • Milestone Pharmaceuticals made up ﹤0.01% of GSA Capital Partners's portfolio in Q3 2026, its #1809 holding.
  • GSA Capital Partners first reported a position in Milestone Pharmaceuticals in Q1 2023 and has held it in 7 quarters since.
  • GSA Capital Partners's Milestone Pharmaceuticals position peaked at $477K in Q4 2025.
  • 74 funds tracked by Wall St. Rank held Milestone Pharmaceuticals as of Q3 2026.

Based on GSA Capital Partners's 13F filing for Q3 2026, filed 16 Nov 2026.